[go: up one dir, main page]

PL3071206T3 - Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie - Google Patents

Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie

Info

Publication number
PL3071206T3
PL3071206T3 PL14815149T PL14815149T PL3071206T3 PL 3071206 T3 PL3071206 T3 PL 3071206T3 PL 14815149 T PL14815149 T PL 14815149T PL 14815149 T PL14815149 T PL 14815149T PL 3071206 T3 PL3071206 T3 PL 3071206T3
Authority
PL
Poland
Prior art keywords
netazepide
osteoporosis
prevention
treatment
gastrin antagonists
Prior art date
Application number
PL14815149T
Other languages
English (en)
Inventor
Irvin Mark MODLIN
Mark Kidd
Original Assignee
CL BioSciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3071206(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CL BioSciences LLC filed Critical CL BioSciences LLC
Publication of PL3071206T3 publication Critical patent/PL3071206T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14815149T 2013-11-22 2014-11-21 Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie PL3071206T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907980P 2013-11-22 2013-11-22
EP14815149.1A EP3071206B1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
PCT/US2014/066832 WO2015077572A1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (1)

Publication Number Publication Date
PL3071206T3 true PL3071206T3 (pl) 2022-01-17

Family

ID=52118000

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14815149T PL3071206T3 (pl) 2013-11-22 2014-11-21 Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie

Country Status (14)

Country Link
US (1) US10709714B2 (pl)
EP (1) EP3071206B1 (pl)
JP (1) JP6502939B2 (pl)
KR (1) KR102254957B1 (pl)
CN (1) CN106163527A (pl)
AU (1) AU2014352875B2 (pl)
BR (1) BR112016011727A2 (pl)
CA (1) CA2929858C (pl)
DK (1) DK3071206T3 (pl)
ES (1) ES2870538T3 (pl)
MX (1) MX2016006657A (pl)
PL (1) PL3071206T3 (pl)
RU (1) RU2693484C1 (pl)
WO (1) WO2015077572A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN115770266B (zh) * 2023-01-30 2023-05-09 云南中医药大学 一种用于治疗绝经后骨质疏松的药物组合物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0348523A4 (en) * 1987-12-22 1991-10-09 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their medicinal use
JPH0374328A (ja) 1989-08-04 1991-03-28 Warner Lambert Co 薬学的活性を有する中枢コレシストキニン拮抗剤
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
JPH07119217B2 (ja) 1990-12-25 1995-12-20 山之内製薬株式会社 新規ベンゾジアゼピン誘導体
WO1993000897A1 (en) 1991-07-12 1993-01-21 Warner-Lambert Company Cholecystokinin antagonists useful in the treatment of panic attacks
CA2120939A1 (en) * 1991-10-11 1993-04-15 Tetsuya Tahara Therapeutic agent for osteoporosis and diazepine compound
AU3247593A (en) * 1991-12-20 1993-07-28 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
IL104853A (en) 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
TW281669B (pl) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
GB2282595A (en) 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IT1261255B (it) 1993-09-09 1996-05-09 Rotta Research Lab Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
CA2239293A1 (en) 1995-12-11 1997-06-19 New England Medical Center Hosptials, Inc. Assay for and uses of peptide hormone receptor ligands
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5922883A (en) 1996-04-03 1999-07-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
NZ511550A (en) 1997-05-12 2005-03-24 Aphton Corp CCK-B/gastrin receptor inhibitors for the treatment of tumors
HUP0101947A3 (en) 1998-05-15 2001-12-28 Aphton Corp Woodland Combination for the treatment of tumors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CN1332743A (zh) 1998-06-04 2002-01-23 艾博特公司 抑制细胞粘附抗炎化合物
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
ES2228451T3 (es) 1999-01-29 2005-04-16 Chugai Seiyaku Kabushiki Kaisha Promotores de condrogenesis y derivados de indolin-2-ona.
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
IL149177A0 (en) 1999-11-05 2002-11-10 Sod Conseils Rech Applic Novel heterocyclic compounds and their use as medicines
WO2001035899A2 (en) 1999-11-19 2001-05-25 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
WO2001077685A2 (en) 2000-04-10 2001-10-18 The General Hospital Corporation Diagnosis and treatment of gastrointestinal disease
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
AU2002252456A1 (en) 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
JPWO2002087620A1 (ja) 2001-04-27 2004-08-12 中外製薬株式会社 軟骨形成促進剤
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20040138207A1 (en) 2001-05-11 2004-07-15 Mayumi Yamano Antitumor agents
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
CN100348196C (zh) 2001-11-13 2007-11-14 詹姆士布莱克基金会有限公司 作为胃泌激素和缩胆囊肽受体配体的苯并三氮杂䓬
JP2005529850A (ja) 2002-02-19 2005-10-06 ファルマシア・イタリア・エス・ピー・エー 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
UA82872C2 (en) 2003-03-28 2008-05-26 Janssen Pharmaceutica Nv Benzo [1,2,5] thiadiazole compounds
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
WO2004101533A1 (en) 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
US20050042283A1 (en) 2003-07-11 2005-02-24 University Of Massachusetts Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
EA200600203A1 (ru) 2003-08-08 2006-08-25 Янссен Фармацевтика, Н. В. Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en) 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
MX2007003623A (es) 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.
US20080124741A1 (en) 2004-10-12 2008-05-29 Heng Dai Canine Cholecystokinin 1 Receptor Materials And Their Use
WO2006049941A2 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
JP2008519078A (ja) 2004-11-04 2008-06-05 ニューロゲン コーポレイション Ｃｂ１拮抗薬としてのアリールアルキル尿素類
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
BRPI0519598A2 (pt) 2004-12-17 2009-03-10 Pfizer derivados de cromano éteis como antagonistas de bomba de Ácido, composiÇço farmacÊutica e uso dos mesmos
EP1839662B1 (en) 2005-01-19 2010-03-24 Zeria Pharmaceutical Co., Ltd. Antitumor agent
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006255047B2 (en) 2005-06-06 2011-09-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating sleep disorders
JP2008543824A (ja) 2005-06-14 2008-12-04 ファイザー株式会社 アシッドポンプアンタゴニストとしてのクロマン置換ベンゾイミダゾール誘導体
ATE425791T1 (de) 2005-07-29 2009-04-15 Rottapharm Spa Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten
WO2007026218A2 (en) 2005-09-01 2007-03-08 Pfizer Japan Inc. Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazole-5-carboxamide derivatives
WO2007072146A1 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
WO2007107827A1 (en) 2006-03-17 2007-09-27 Raqualia Pharma Inc. Chromane derivatives
CA2649000A1 (en) 2006-04-12 2007-10-18 Merck Patent Gesellschaft Mit Beschraenkter Haftung N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
FR2901473B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
FR2901472B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
KR101109866B1 (ko) 2006-09-21 2012-04-12 라퀄리아 파마 인코포레이티드 선택성 산 펌프 억제제로서의 벤즈이미다졸 유도체
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2008124518A1 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
RU2379043C2 (ru) * 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
US20110105515A1 (en) 2007-08-07 2011-05-05 President And Fellows Of Harvard College Targeting the oncoprotein nucleophosmin
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
CN102333763A (zh) 2009-03-31 2012-01-25 善利亚新药工业股份有限公司 1,5-苯二氮䓬衍生物的制备方法
KR101605063B1 (ko) 2009-07-09 2016-03-21 라퀄리아 파마 인코포레이티드 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제
EP2480549B1 (en) 2009-09-24 2015-04-08 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Fused imidazo[3,2-d]pyrazines as PI3 kinase inhibitors
CN102665718B (zh) 2009-10-06 2016-03-09 米伦纽姆医药公司 可用作pdk1抑制剂的杂环化合物
WO2011060304A2 (en) 2009-11-13 2011-05-19 Constar International, Inc. Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
BR112012026641A2 (pt) 2010-04-23 2016-07-12 Kineta Inc compostos antivirais
US9000054B2 (en) 2010-08-12 2015-04-07 Senomyx, Inc. Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
US20130281523A1 (en) 2010-11-18 2013-10-24 Peter LETENDRE Low dose cannabinoid medicaments
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
ES2650744T3 (es) 2010-12-14 2018-01-22 Electrophoretics Limited Inhibidores de la caseína quinasa 1 delta (CK1delta)
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
JP6210996B2 (ja) 2011-11-07 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー Ｚ選択的オレフィンメタセシスのためのタングステンオキソアルキリデン錯体
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors

Also Published As

Publication number Publication date
DK3071206T3 (da) 2021-05-25
JP6502939B2 (ja) 2019-04-17
AU2014352875A1 (en) 2016-05-26
US20150148339A1 (en) 2015-05-28
EP3071206A1 (en) 2016-09-28
RU2016124538A (ru) 2017-12-27
CN106163527A (zh) 2016-11-23
AU2014352875B2 (en) 2019-10-24
CA2929858C (en) 2022-03-29
ES2870538T3 (es) 2021-10-27
US10709714B2 (en) 2020-07-14
EP3071206B1 (en) 2021-02-17
KR20160088891A (ko) 2016-07-26
RU2693484C1 (ru) 2019-07-03
MX2016006657A (es) 2016-10-12
WO2015077572A1 (en) 2015-05-28
BR112016011727A2 (pt) 2017-08-08
JP2016538295A (ja) 2016-12-08
KR102254957B1 (ko) 2021-05-25
AU2014352875A8 (en) 2016-06-30
CA2929858A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
IL256245A (en) Treatments combining a pd-l1 antagonist
ES3048688T3 (en) High dosage strength tablets of rucaparib
GB201412867D0 (en) Respiratory therapy devices
GB2538021B (en) Locking device
PL2942457T3 (pl) Zamek
GB201407571D0 (en) Respiratory therapy devices
SG11201707719WA (en) Dispersible dosage form
GB2521853B (en) High security blanket
GB2558853B (en) Lock device
GB2558141B (en) Lock Device
GB201415806D0 (en) Locking device
GB2520163B (en) Fall prevention apparatus
GB201610219D0 (en) Locking device
GB201515453D0 (en) Respiratory therapy devices
PL3071206T3 (pl) Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie
IL231816A (en) Bone fracture treatment devices
GB2539034B (en) Straps for security devices
GB2547829B (en) Shoulder effect reduction
PL3144455T3 (pl) Urządzenie ryglujące
GB201413476D0 (en) Boris safety devices
GB201513787D0 (en) Respiratory therapy devices
GB201402314D0 (en) Locking apparatus
GB201509433D0 (en) Shoulder arthroplasty device
TWM489195U (en) Locking device for electronic device
GB2533741B (en) Locking apparatus